Panelists discuss how future bronchiectasis research will focus on precision medicine, identify treatable traits, and expand networks of Centers of Excellence to provide advanced care and clinical ...

Non–cystic fibrosis bronchiectasis (NCFB) is a chronic inflammatory condition of the lungs associated with respiratory infections and daily cough and sputum. Non-cystic fibrosis bronchiectasis. Image ...

Please provide your email address to receive an email when new articles are posted on . The FDA based brensocatib’s approval on phase 3 ASPEN and phase 2 WILLOW trial results. This marks the first ...

Please provide your email address to receive an email when new articles are posted on . The population-based cohort study included 3,858,422 participants from the 2009 National Health Screening ...

Brensocatib is the first approved therapy for non–cystic fibrosis bronchiectasis and the first dipeptidyl peptidase 1 inhibitor for neutrophil-mediated diseases. The ASPEN trial showed brensocatib ...

Bronchiectasis and chronic obstructive pulmonary disease (COPD) are two chronic conditions that involve damage to the lungs. The causes and treatments for each differ. In some instances, COPD may ...

In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP-1) ...

MPR: What is non-cystic fibrosis bronchiectasis? Dr Addrizzo-Harris: Non-cystic fibrosis bronchiectasis is an abnormality of the airways in the lung where the airways become dilated, often permanently ...

New research underscores how air pollution and temperature extremes amplify risks for bronchiectasis patients, pointing to critical measures for safeguarding vulnerable groups. Study: Association of ...